The Gold Trade, May 24
Health Care: Drugs
Orexigen Therapeutics Inc. (OREX: NASDAQ)
$6.45 -0.03 | -0.46%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.45 |
| 52 Week High | 7.73 |
| 52 Week Low | 3.10 |
| Avg. Daily Vol. (Mil) | 1.12 |
| Beta (3 year) | 2.69 |
| Share Related Items | |
| Mkt Cap (Mil) | 610.44 |
| Shares Out (Mil) | 94.64 |
| Float (Mil) | 85.16 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.60 |
| Current Ratio | 5.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 178.08 |
| Price/Book | 10.41 |
| Price/Cash Flow | -5.60 |
| Per Share Data | |
| Earnings | -1.32 |
| Sales | 0.04 |
| Book Value | 0.62 |
| Cash Flow | -1.15 |
| Business Summary | |
|---|---|
| A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. | |
| General Information | |
| 3344 North Torrey Pines Cour
Suite 200 La Jolla, CA 92037 |
|
| www.orexigen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 41 | |
| CEO: Michael A. Narachi | |
| Short Interest | |
| Current Month (Mil) | 8.39 |
| Previous Month (Mil) | 8.23 |
| Short Interest Ratio (Days) | 9.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -93.80 |
| Return on Investments | -186.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with OREX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Usermy picks
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
Latest OREX Headlines from TheStreet
- Commit To Purchase Orexigen Therapeutics At $3, Earn 23.3% 05.23.13 | 02:05 pm
- 5 Stocks Under $10 Set to Soar 05.23.13 | 01:05 pm
- 8 Stocks Under $10 Moving Higher 02.28.13 | 11:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Two 01.08.13 | 11:01 am
- J.P. Morgan: Biotech Stocks Heading Higher in 2013 01.02.13 | 07:01 am
- Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Vivus Weight-Loss Drug's Failing Math 10.31.12 | 01:10 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Orexigen Therapeutics' CEO Presents At Bank Of America Merrill Lynch Global Healthcare Conference - Special Call Transcript 09.13.12 | 12:09 pm
- Orexigen Therapeutics' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.12.12 | 12:09 pm
Press Releases for OREX
- Orexigen Therapeutics To Host Full Year And Fourth Quarter 2012 Financial Results Conference Call And Webcast - PR Newswire 03.07.13 | 08:03 am
- Orexigen Therapeutics Announces Progress With FDA On A Faster Path To Resubmission Of The Contrave NDA - PR Newswire 01.07.13 | 08:01 am
- Orexigen Therapeutics Concludes Light Study Patient Screening, Expecting To Randomize Approximately 9,000 Patients, And Presents New Obesity Therapeutics Market Research - PR Newswire 12.18.12 | 08:12 am
- Orexigen Therapeutics To Host Analyst Day Event On December 18, 2012 - PR Newswire 12.04.12 | 08:12 am
- Orexigen Therapeutics Schedules November 7, 2012 Conference Call And Webcast Discussion Of Financial Results For The Third Quarter Ended September 30, 2012 - PR Newswire 10.31.12 | 08:10 am
- Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion Of Financial Results For The Second Quarter Ended June 30, 2012 - PR Newswire 07.31.12 | 04:07 pm
- Orexigen® Therapeutics And Sharecare® Announce Partnership For WeightMateâ¢, A Comprehensive Weight Management Program - PR Newswire 06.06.12 | 06:06 am
- The Light Study, A Long-Term Research Study Of Investigational Weight Loss Drug Contrave®, Begins Enrolling Patients Nationwide - PR Newswire 06.06.12 | 06:06 am
- Orexigen® Therapeutics Completes Public Offering Of Common Stock And Warrants To Purchase Common Stock - PR Newswire 12.22.11 | 04:12 pm
- Orexigen Therapeutics To Present At The Lazard Capital Markets Healthcare Conference - PR Newswire 11.11.11 | 08:11 am
Partner Headlines for OREX
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - NASDAQ 09.20.12 | 10:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - Zacks 09.20.12 | 06:09 pm
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Arena And Vivus Set To Dominate The Obesity Drug Market - Seeking Alpha 08.30.12 | 09:08 am
- Arena Cuts Loss, Sales Climb - Analyst Blog - Zacks 08.14.12 | 09:08 am
- Earnings Preview: Vivus - Seeking Alpha 08.04.12 | 07:08 am
